France· FR:67810869
SYNAGIS 100 mg/ml, solution injectable
A medicinal product containing palivizumab, registered in France by ASTRAZENECA AB.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PALIVIZUMAB
- Manufacturer
- ASTRAZENECA AB
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009300723251 flacon(s) en verre de 1 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSynagis2care4 ApS
- United StatesSynagisSwedish Orphan Biovitrum AB (publ)
- IrelandSynagis 50 mg/0.5 ml and 100 mg/1 ml Solution for injectionAstraZeneca AB
- NetherlandsSynagis 100 mg/ml, oplossing voor injectieAstraZeneca AB
- BelgiumSynagis 100 mgAstraZeneca
- United KingdomSynagis 100mg powder and solvent for solution for injection vialsAbbVie Ltd
- NorwaySynagisAstraZeneca
- SpainSYNAGIS 100 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEAstrazeneca Ab
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d90215f8-1f80-442c-9b70-24d66313d74a GET /v1/drugs/d90215f8-1f80-442c-9b70-24d66313d74a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67810869",
"date_amm": "2014-08-22",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/99/117",
"substance": "PALIVIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "intramusculaire",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.